WEKO3
アイテム
{"_buckets": {"deposit": "5da488a9-71e4-4405-93fa-23d39104492e"}, "_deposit": {"created_by": 2, "id": "1263", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "1263"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00001263", "sets": ["74"]}, "author_link": ["5868", "5870", "5867", "5871", "5869"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-08-05", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "181", "bibliographicPageStart": "173", "bibliographicVolumeNumber": "548", "bibliographic_titles": [{"bibliographic_title": "International Journal of Pharmaceutics"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "A requirement of gene therapy is efficient nucleic acid delivery. However, the application of cationic liposomes to gene therapy is restricted by their inefficient transfection capacity, which may be caused by cytotoxicity. This cytotoxicity is highly dependent on cationic lipid-induced reactive oxygen species (ROS). Here, to provide cellular protection, we used edaravone, an efficacious anti-oxidative drug, to scavenge ROS during transfection using cationic liposome/plasmid DNA complexes (lipoplexes). Both free edaravone and edaravone-loaded liposomes (EDLPs) enhanced transgene expression in the human hepatoma cell line, HepG2, while EDLPs decreased the effective dose of edaravone. The cellular protective effect of edaravone was found to decrease the cytotoxicity of cationic liposomes. Edaravone was also effective in the commercial product, LipofectamineR 3000, which may expand the application of edaravone to promote transfection efficiency. Compared with free edaravone, EDLPs also showed superior transgene expression in mice. Our findings will promote the development of efficient and safe gene therapy.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "International Journal of Pharmaceutics, 548(1), pp.173-181; 2018", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier B.V."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.ijpharm.2018.06.068", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2018 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03785173", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Wang, Shu"}], "nameIdentifiers": [{"nameIdentifier": "5867", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fumoto, Shintaro"}], "nameIdentifiers": [{"nameIdentifier": "5868", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyamoto, Hirotaka"}], "nameIdentifiers": [{"nameIdentifier": "5869", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Masakazu"}], "nameIdentifiers": [{"nameIdentifier": "5870", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishida, Koyo"}], "nameIdentifiers": [{"nameIdentifier": "5871", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "IJP548_173.pdf", "filesize": [{"value": "682.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 682300.0, "url": {"label": "IJP548_173.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/1263/files/IJP548_173.pdf"}, "version_id": "90c63caf-ab09-431a-a975-17ff444fb402"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Cationic liposomes", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cytoprotection", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Edaravone", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-viral vector", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Reactive oxygen species", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Transfection", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Edaravone, a cytoprotective drug, enhances transgene expression mediated by lipoplexes in HepG2 cells and mice", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Edaravone, a cytoprotective drug, enhances transgene expression mediated by lipoplexes in HepG2 cells and mice"}]}, "item_type_id": "2", "owner": "2", "path": ["74"], "permalink_uri": "http://hdl.handle.net/10069/38520", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-09-05"}, "publish_date": "2019-09-05", "publish_status": "0", "recid": "1263", "relation": {}, "relation_version_is_last": true, "title": ["Edaravone, a cytoprotective drug, enhances transgene expression mediated by lipoplexes in HepG2 cells and mice"], "weko_shared_id": -1}
Edaravone, a cytoprotective drug, enhances transgene expression mediated by lipoplexes in HepG2 cells and mice
http://hdl.handle.net/10069/38520
http://hdl.handle.net/10069/38520d12192a6-d558-4b9b-aeb8-bdd8a4cc4cd2
名前 / ファイル | ライセンス | アクション |
---|---|---|
IJP548_173.pdf (682.3 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-09-05 | |||||
タイトル | ||||||
タイトル | Edaravone, a cytoprotective drug, enhances transgene expression mediated by lipoplexes in HepG2 cells and mice | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Cationic liposomes | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Cytoprotection | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Edaravone | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Non-viral vector | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Reactive oxygen species | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Transfection | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Wang, Shu
× Wang, Shu× Fumoto, Shintaro× Miyamoto, Hirotaka× Tanaka, Masakazu× Nishida, Koyo |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | A requirement of gene therapy is efficient nucleic acid delivery. However, the application of cationic liposomes to gene therapy is restricted by their inefficient transfection capacity, which may be caused by cytotoxicity. This cytotoxicity is highly dependent on cationic lipid-induced reactive oxygen species (ROS). Here, to provide cellular protection, we used edaravone, an efficacious anti-oxidative drug, to scavenge ROS during transfection using cationic liposome/plasmid DNA complexes (lipoplexes). Both free edaravone and edaravone-loaded liposomes (EDLPs) enhanced transgene expression in the human hepatoma cell line, HepG2, while EDLPs decreased the effective dose of edaravone. The cellular protective effect of edaravone was found to decrease the cytotoxicity of cationic liposomes. Edaravone was also effective in the commercial product, LipofectamineR 3000, which may expand the application of edaravone to promote transfection efficiency. Compared with free edaravone, EDLPs also showed superior transgene expression in mice. Our findings will promote the development of efficient and safe gene therapy. | |||||
書誌情報 |
International Journal of Pharmaceutics 巻 548, 号 1, p. 173-181, 発行日 2018-08-05 |
|||||
出版者 | ||||||
出版者 | Elsevier B.V. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 03785173 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.ijpharm.2018.06.068 | |||||
権利 | ||||||
権利情報 | c 2018 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | International Journal of Pharmaceutics, 548(1), pp.173-181; 2018 |